首页 > 最新文献

Journal of Intensive Care最新文献

英文 中文
Hemorrhages and risk factors in patients undergoing thromboprophylaxis in a respiratory critical care unit: a secondary data analysis of a cohort study. 呼吸重症监护病房接受血栓预防治疗的患者的出血情况和风险因素:一项队列研究的二次数据分析。
IF 3.8 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-10-29 DOI: 10.1186/s40560-024-00756-w
Wen-Rui Lyu, Xiao Tang, Yu Jin, Rui Wang, Xu-Yan Li, Ying Li, Chun-Yan Zhang, Wei Zhao, Zhao-Hui Tong, Bing Sun

Objective: To verify whether the bleeding risk assessment guidelines from the 9th American College of Chest Physicians (ACCP) are prognostic for respiratory intensive care unit (RICU) patients and to explore risk factors for hemorrhages, we conducted a secondary data analysis based on our previously published cohort study of venous thromboembolism.

Patients and methods: We performed a secondary data analysis on the single-center prospective cohort from our previous study. Patients admitted to the RICU at Beijing Chao-Yang Hospital from August 1, 2014 to December 31, 2020 were included and followed up until discharge.

Results: The study enrolled 931 patients, of which 715 (76.8%) were at high risk of bleeding, while the remaining were at low risk. Of the total, 9.2% (86/931) suffered major bleeding, and no significant difference was found between the two risk groups (p = 0.601). High-risk patients had poor outcomes, including higher mortality and longer stays. Independent risk factors for major bleeding were APACHE II score ≥ 15; invasive pulmonary aspergillosis; therapeutic dose of anticoagulants; extracorporeal membrane oxygenation; and continuous renal replacement therapy. Blood transfusion not related to bleeding appeared to be an independent protective factor for major bleeding (OR 0.099, 95% CI 0.045-0.218, p < 0.001).

Conclusion: Bleeding risk assessment models from the 9th ACCP guidelines may not be suitable for patients in RICU. Building a bleeding risk assessment model that is suitable for patients in all RICUs remains a challenge. Trial registration ClinicalTrials.gov: NCT02213978.

目的为了验证第九届美国胸科医师学会(ACCP)出血风险评估指南对呼吸重症监护病房(RICU)患者的预后是否有效,并探讨出血的风险因素,我们在之前发表的静脉血栓栓塞症队列研究的基础上进行了二次数据分析:我们对之前研究中的单中心前瞻性队列进行了二次数据分析。研究纳入了 2014 年 8 月 1 日至 2020 年 12 月 31 日入住北京朝阳医院 RICU 的患者,并随访至出院:研究共纳入 931 例患者,其中 715 例(76.8%)为出血高风险患者,其余为低风险患者。其中,9.2%(86/931)的患者出现大出血,两个风险组之间无明显差异(P = 0.601)。高风险患者的预后较差,包括死亡率较高和住院时间较长。大出血的独立风险因素包括:APACHE II评分≥15分;侵袭性肺部曲霉菌病;抗凝药物治疗剂量;体外膜氧合;持续肾脏替代治疗。与出血无关的输血似乎是大出血的一个独立保护因素(OR 0.099,95% CI 0.045-0.218,P 结论):第 9 版 ACCP 指南中的出血风险评估模型可能不适合 RICU 患者。建立适合所有 RICU 患者的出血风险评估模型仍是一项挑战。试验注册 ClinicalTrials.gov:NCT02213978。
{"title":"Hemorrhages and risk factors in patients undergoing thromboprophylaxis in a respiratory critical care unit: a secondary data analysis of a cohort study.","authors":"Wen-Rui Lyu, Xiao Tang, Yu Jin, Rui Wang, Xu-Yan Li, Ying Li, Chun-Yan Zhang, Wei Zhao, Zhao-Hui Tong, Bing Sun","doi":"10.1186/s40560-024-00756-w","DOIUrl":"10.1186/s40560-024-00756-w","url":null,"abstract":"<p><strong>Objective: </strong>To verify whether the bleeding risk assessment guidelines from the 9th American College of Chest Physicians (ACCP) are prognostic for respiratory intensive care unit (RICU) patients and to explore risk factors for hemorrhages, we conducted a secondary data analysis based on our previously published cohort study of venous thromboembolism.</p><p><strong>Patients and methods: </strong>We performed a secondary data analysis on the single-center prospective cohort from our previous study. Patients admitted to the RICU at Beijing Chao-Yang Hospital from August 1, 2014 to December 31, 2020 were included and followed up until discharge.</p><p><strong>Results: </strong>The study enrolled 931 patients, of which 715 (76.8%) were at high risk of bleeding, while the remaining were at low risk. Of the total, 9.2% (86/931) suffered major bleeding, and no significant difference was found between the two risk groups (p = 0.601). High-risk patients had poor outcomes, including higher mortality and longer stays. Independent risk factors for major bleeding were APACHE II score ≥ 15; invasive pulmonary aspergillosis; therapeutic dose of anticoagulants; extracorporeal membrane oxygenation; and continuous renal replacement therapy. Blood transfusion not related to bleeding appeared to be an independent protective factor for major bleeding (OR 0.099, 95% CI 0.045-0.218, p < 0.001).</p><p><strong>Conclusion: </strong>Bleeding risk assessment models from the 9th ACCP guidelines may not be suitable for patients in RICU. Building a bleeding risk assessment model that is suitable for patients in all RICUs remains a challenge. Trial registration ClinicalTrials.gov: NCT02213978.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":"12 1","pages":"43"},"PeriodicalIF":3.8,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11520846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autophagy and autophagic cell death in sepsis: friend or foe? 败血症中的自噬和自噬细胞死亡:是敌是友?
IF 3.8 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-10-25 DOI: 10.1186/s40560-024-00754-y
Toshiaki Iba, Julie Helms, Cheryl L Maier, Ricard Ferrer, Jerrold H Levy

In sepsis, inflammation, and nutrient deficiencies endanger cellular homeostasis and survival. Autophagy is primarily a mechanism of cellular survival under fasting conditions. However, autophagy-dependent cell death, known as autophagic cell death, is proinflammatory and can exacerbate sepsis. Autophagy also regulates various types of non-inflammatory and inflammatory cell deaths. Non-inflammatory apoptosis tends to suppress inflammation, however, inflammatory necroptosis, pyroptosis, ferroptosis, and autophagic cell death lead to the release of inflammatory cytokines and damage-associated molecular patterns (DAMPs) and amplify inflammation. The selection of cell death mechanisms is complex and often involves a mixture of various styles. Similarly, protective autophagy and lethal autophagy may be triggered simultaneously in cells. How cells balance the regulatory mechanisms of these processes is an area of interest that is still under investigation. Therapies aimed at modulating autophagy are considered promising. Enhancing autophagy helps clear and recycle damaged organelles and reduce the burden of inflammatory processes while inhibiting excessive autophagy, which could prevent autophagic cell death. In this review, we introduce recent advances in research and the complex regulatory system of autophagy in sepsis.

败血症、炎症和营养缺乏会危及细胞的稳态和生存。自噬主要是细胞在禁食条件下的一种生存机制。然而,依赖自噬的细胞死亡(即自噬细胞死亡)会促发炎症,并加剧败血症。自噬还能调节各种类型的非炎症性和炎症性细胞死亡。非炎症性细胞凋亡往往会抑制炎症,但炎症性坏死、热凋亡、铁凋亡和自噬细胞死亡会导致炎性细胞因子和损伤相关分子模式(DAMP)的释放,并扩大炎症。细胞死亡机制的选择是复杂的,往往涉及各种方式的混合。同样,细胞中可能同时触发保护性自噬和致死性自噬。细胞如何平衡这些过程的调控机制是一个仍在研究的领域。旨在调节自噬的疗法被认为很有前景。加强自噬有助于清除和回收受损细胞器,减轻炎症过程的负担,同时抑制过度自噬,防止自噬细胞死亡。在这篇综述中,我们将介绍最近的研究进展以及败血症中自噬的复杂调控系统。
{"title":"Autophagy and autophagic cell death in sepsis: friend or foe?","authors":"Toshiaki Iba, Julie Helms, Cheryl L Maier, Ricard Ferrer, Jerrold H Levy","doi":"10.1186/s40560-024-00754-y","DOIUrl":"10.1186/s40560-024-00754-y","url":null,"abstract":"<p><p>In sepsis, inflammation, and nutrient deficiencies endanger cellular homeostasis and survival. Autophagy is primarily a mechanism of cellular survival under fasting conditions. However, autophagy-dependent cell death, known as autophagic cell death, is proinflammatory and can exacerbate sepsis. Autophagy also regulates various types of non-inflammatory and inflammatory cell deaths. Non-inflammatory apoptosis tends to suppress inflammation, however, inflammatory necroptosis, pyroptosis, ferroptosis, and autophagic cell death lead to the release of inflammatory cytokines and damage-associated molecular patterns (DAMPs) and amplify inflammation. The selection of cell death mechanisms is complex and often involves a mixture of various styles. Similarly, protective autophagy and lethal autophagy may be triggered simultaneously in cells. How cells balance the regulatory mechanisms of these processes is an area of interest that is still under investigation. Therapies aimed at modulating autophagy are considered promising. Enhancing autophagy helps clear and recycle damaged organelles and reduce the burden of inflammatory processes while inhibiting excessive autophagy, which could prevent autophagic cell death. In this review, we introduce recent advances in research and the complex regulatory system of autophagy in sepsis.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":"12 1","pages":"41"},"PeriodicalIF":3.8,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11520123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Three-month outcomes and cost-effectiveness of interferon gamma-1b in critically ill patients: a secondary analysis of the PREV-HAP trial. 重症患者使用γ-1b干扰素三个月的疗效和成本效益:PREV-HAP试验的二次分析。
IF 3.8 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-10-11 DOI: 10.1186/s40560-024-00753-z
Marwan Bouras, Philippe Tessier, Cécile Poulain, Solène Schirr-Bonnans, Antoine Roquilly

Background: Interferon gamma‑1b has been proposed to treat critical illness-induced immunosuppression. We aimed to determine the effects on 90-day outcomes and the cost-effectiveness of interferon gamma‑1b compared to placebo in mechanically ventilated critically ill patients.

Methods: A cost-effectiveness analysis (CEA) was embedded in the "PREV-HAP trial", a multicenter, placebo‑controlled, randomized trial, which randomly assigned critically ill adults under mechanical ventilation to receive interferon gamma or placebo. The CEA compared interferon-gamma with placebo using a collective perspective at a 90-day time horizon. The primary outcome was the incremental cost-effectiveness ratio (ICER) expressed in terms of adjusted cost per adjusted Quality-Adjusted Life-Years (QALYs) gained. QALYs were estimated from the responses of patients and proxy respondents to the health-related quality of life questionnaire EQ-5D-3L.

Results: The 109 patients in the PREV-HAP trial were included in the CEA. At day 90, all-cause mortality rates were 23.6% in the interferon group and 25% in the placebo group (Odds Ratio (OR) = 0.88 (0.40 -1.93) p = 0.67). The difference in the mean adjusted costs per patient at 90 days was €-1.638 (95%CI €-17.534 to €11.968) in favor of interferon gamma-1b. The mean difference in adjusted QALYs between interferon gamma-1b and the placebo group was + 0.019 (95%CI -0.005 to 0.043). The probability that interferon gamma-1b was cost-effective ranged from 0.60 to 0.71 for a willingness to pay a QALY between €20k and €150k for the base case analysis.

Conclusion: Early administration of interferon gamma might be cost-effective in critically ill patients supporting the realization of other studies on this treatment. However, the generalization of the findings should be considered cautiously, given the small sample size due to the premature end of PREV-HAP. Trial registration ClinicalTrials.gov Identifier: NCT04793568, Registration date: 2021-02-24.

背景:有人建议用γ-1b干扰素治疗危重病人引起的免疫抑制。我们旨在确定干扰素 gamma-1b 与安慰剂相比对机械通气危重症患者 90 天预后的影响以及成本效益:PREV-HAP试验 "是一项多中心、安慰剂对照随机试验,随机分配接受机械通气的成人重症患者接受γ干扰素或安慰剂治疗。CEA 以 90 天为时间跨度,从集体角度对干扰素-γ 和安慰剂进行了比较。主要结果是增量成本效益比 (ICER),以每获得 1 个调整后质量调整生命年 (QALY) 的调整后成本表示。QALYs根据患者和代理受访者对健康相关生活质量问卷EQ-5D-3L的回答进行估算:PREV-HAP试验的109名患者被纳入CEA。第 90 天时,干扰素组的全因死亡率为 23.6%,安慰剂组为 25%(比值比 (OR) = 0.88 (0.40 -1.93) p = 0.67)。每名患者 90 天的平均调整成本差异为 1.638 欧元(95%CI 为 17.534 欧元至 11.968 欧元),干扰素 gamma-1b 更优。干扰素γ-1b组与安慰剂组的调整后QALYs平均差异为+ 0.019(95%CI为-0.005至0.043)。在基础病例分析中,如果QALY的支付意愿在2万欧元至15万欧元之间,则干扰素γ-1b具有成本效益的概率为0.60至0.71:结论:对重症患者而言,早期使用γ干扰素可能具有成本效益,这与其他有关该疗法的研究结果相吻合。然而,由于PREV-HAP过早结束,样本量较小,因此应谨慎考虑研究结果的推广。试验注册 ClinicalTrials.gov Identifier:NCT04793568,注册日期:2021-02-24。
{"title":"Three-month outcomes and cost-effectiveness of interferon gamma-1b in critically ill patients: a secondary analysis of the PREV-HAP trial.","authors":"Marwan Bouras, Philippe Tessier, Cécile Poulain, Solène Schirr-Bonnans, Antoine Roquilly","doi":"10.1186/s40560-024-00753-z","DOIUrl":"10.1186/s40560-024-00753-z","url":null,"abstract":"<p><strong>Background: </strong>Interferon gamma‑1b has been proposed to treat critical illness-induced immunosuppression. We aimed to determine the effects on 90-day outcomes and the cost-effectiveness of interferon gamma‑1b compared to placebo in mechanically ventilated critically ill patients.</p><p><strong>Methods: </strong>A cost-effectiveness analysis (CEA) was embedded in the \"PREV-HAP trial\", a multicenter, placebo‑controlled, randomized trial, which randomly assigned critically ill adults under mechanical ventilation to receive interferon gamma or placebo. The CEA compared interferon-gamma with placebo using a collective perspective at a 90-day time horizon. The primary outcome was the incremental cost-effectiveness ratio (ICER) expressed in terms of adjusted cost per adjusted Quality-Adjusted Life-Years (QALYs) gained. QALYs were estimated from the responses of patients and proxy respondents to the health-related quality of life questionnaire EQ-5D-3L.</p><p><strong>Results: </strong>The 109 patients in the PREV-HAP trial were included in the CEA. At day 90, all-cause mortality rates were 23.6% in the interferon group and 25% in the placebo group (Odds Ratio (OR) = 0.88 (0.40 -1.93) p = 0.67). The difference in the mean adjusted costs per patient at 90 days was €-1.638 (95%CI €-17.534 to €11.968) in favor of interferon gamma-1b. The mean difference in adjusted QALYs between interferon gamma-1b and the placebo group was + 0.019 (95%CI -0.005 to 0.043). The probability that interferon gamma-1b was cost-effective ranged from 0.60 to 0.71 for a willingness to pay a QALY between €20k and €150k for the base case analysis.</p><p><strong>Conclusion: </strong>Early administration of interferon gamma might be cost-effective in critically ill patients supporting the realization of other studies on this treatment. However, the generalization of the findings should be considered cautiously, given the small sample size due to the premature end of PREV-HAP. Trial registration ClinicalTrials.gov Identifier: NCT04793568, Registration date: 2021-02-24.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":"12 1","pages":"40"},"PeriodicalIF":3.8,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11468134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Monte Carlo simulations of cefepime in children receiving continuous kidney replacement therapy support continuous infusions for target attainment. 对接受持续肾脏替代疗法的儿童进行头孢吡肟的蒙特卡洛模拟,支持持续输注以达到目标。
IF 3.8 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-10-08 DOI: 10.1186/s40560-024-00752-0
H Rhodes Hambrick, Nieko Punt, Kathryn Pavia, Tomoyuki Mizuno, Stuart L Goldstein, Sonya Tang Girdwood

Background: Sepsis is a leading cause of acute kidney injury requiring continuous kidney replacement therapy (CKRT) and CKRT can alter drug pharmacokinetics (PK). Cefepime is used commonly in critically ill children and is cleared by CKRT, yet data regarding cefepime PK and pharmacodynamic (PD) target attainment in children receiving CKRT are scarce, so we performed Monte Carlo simulations (MCS) of cefepime dosing strategies in children receiving CKRT.

Methods: We developed a CKRT "module" in the precision dosing software Edsim++. The module was added into a pediatric cefepime PK model. 1000-fold MCS were performed using six dosing strategies in patients aged 2-25 years and ≥ 10 kg with differing residual kidney function (estimated glomerular filtration rate of 5 vs 30 mL/min/1.73 m2), CKRT prescriptions, (standard-dose total effluent flow of 2500 mL/h/1.73 m2 vs high-dose of 8000 mL/h/1.73 m2), and fluid accumulation (0-30%). Probability of target attainment (PTA) was defined by percentage of patients with free concentrations exceeding bacterial minimum inhibitory concentration (MIC) for 100% of the dosing interval (100% fT > 1xMIC) and 4xMIC using an MIC of 8 mg/L for Pseudomonas aeruginosa.

Results: Assuming standard-dose dialysis and minimal kidney function, > 90% PTA was achieved for 100% fT > 1x MIC with continuous infusions (CI) of 100-150 mg/kg/day (max 4/6 g) and 4-h infusions of 50 mg/kg (max 2 g), but > 90% PTA for 100% fT > 4x MIC was only achieved by 150 mg/kg CI. Decreased PTA was seen with less frequent dosing, shorter infusions, higher-dose CKRT, and higher residual kidney function.

Conclusions: Our new CKRT-module was successfully added to an existing cefepime PK model for MCS in young patients on CKRT. When targeting 100% fT > 4xMIC or using higher-dose CKRT, CI would allow for higher PTA than intermittent dosing.

背景:脓毒症是导致急性肾损伤的主要原因,需要进行持续肾脏替代治疗(CKRT),而CKRT会改变药物的药代动力学(PK)。头孢吡肟是重症儿童的常用药物,可通过 CKRT 清除,但有关接受 CKRT 儿童的头孢吡肟 PK 和药效学 (PD) 达标情况的数据却很少,因此我们对接受 CKRT 儿童的头孢吡肟给药策略进行了蒙特卡罗模拟 (MCS):方法:我们在精确给药软件 Edsim++ 中开发了一个 CKRT "模块"。方法:我们在精确给药软件 Edsim++ 中开发了 CKRT "模块",并将该模块添加到小儿头孢吡肟 PK 模型中。我们使用六种给药策略对 2-25 岁、体重≥ 10 kg 的患者进行了 1000 倍 MCS 分析,这些患者的残余肾功能(估计肾小球滤过率为 5 vs 30 mL/min/1.73 m2)、CKRT 处方(标准剂量总流出流量为 2500 mL/h/1.73 m2 vs 高剂量为 8000 mL/h/1.73 m2)和体液蓄积(0-30%)各不相同。达到目标的概率(PTA)是指在 100%的给药间隔内(100% fT > 1xMIC),游离浓度超过细菌最低抑菌浓度(MIC)的患者百分比,铜绿假单胞菌的 MIC 为 8 mg/L,则游离浓度为 4xMIC:假设采用标准剂量透析且肾功能极差,连续输注(CI)100-150 毫克/千克/天(最大 4/6 克)和 4 小时输注 50 毫克/千克(最大 2 克),100% fT > 1x MIC 的 PTA > 90%,但 100% fT > 4x MIC 的 PTA > 90%,只有 150 毫克/千克 CI 才能达到。用药次数少、输液时间短、CKRT 剂量大、残余肾功能高时,PTA 会降低:我们的新 CKRT 模块成功地添加到了现有的头孢吡肟 PK 模型中,用于治疗接受 CKRT 的年轻患者的 MCS。当目标值为 100% fT > 4xMIC 或使用较高剂量的 CKRT 时,CI 可使 PTA 高于间歇给药。
{"title":"Monte Carlo simulations of cefepime in children receiving continuous kidney replacement therapy support continuous infusions for target attainment.","authors":"H Rhodes Hambrick, Nieko Punt, Kathryn Pavia, Tomoyuki Mizuno, Stuart L Goldstein, Sonya Tang Girdwood","doi":"10.1186/s40560-024-00752-0","DOIUrl":"10.1186/s40560-024-00752-0","url":null,"abstract":"<p><strong>Background: </strong>Sepsis is a leading cause of acute kidney injury requiring continuous kidney replacement therapy (CKRT) and CKRT can alter drug pharmacokinetics (PK). Cefepime is used commonly in critically ill children and is cleared by CKRT, yet data regarding cefepime PK and pharmacodynamic (PD) target attainment in children receiving CKRT are scarce, so we performed Monte Carlo simulations (MCS) of cefepime dosing strategies in children receiving CKRT.</p><p><strong>Methods: </strong>We developed a CKRT \"module\" in the precision dosing software Edsim++. The module was added into a pediatric cefepime PK model. 1000-fold MCS were performed using six dosing strategies in patients aged 2-25 years and ≥ 10 kg with differing residual kidney function (estimated glomerular filtration rate of 5 vs 30 mL/min/1.73 m<sup>2</sup>), CKRT prescriptions, (standard-dose total effluent flow of 2500 mL/h/1.73 m<sup>2</sup> vs high-dose of 8000 mL/h/1.73 m<sup>2</sup>), and fluid accumulation (0-30%). Probability of target attainment (PTA) was defined by percentage of patients with free concentrations exceeding bacterial minimum inhibitory concentration (MIC) for 100% of the dosing interval (100% fT > 1xMIC) and 4xMIC using an MIC of 8 mg/L for Pseudomonas aeruginosa.</p><p><strong>Results: </strong>Assuming standard-dose dialysis and minimal kidney function, > 90% PTA was achieved for 100% fT > 1x MIC with continuous infusions (CI) of 100-150 mg/kg/day (max 4/6 g) and 4-h infusions of 50 mg/kg (max 2 g), but > 90% PTA for 100% fT > 4x MIC was only achieved by 150 mg/kg CI. Decreased PTA was seen with less frequent dosing, shorter infusions, higher-dose CKRT, and higher residual kidney function.</p><p><strong>Conclusions: </strong>Our new CKRT-module was successfully added to an existing cefepime PK model for MCS in young patients on CKRT. When targeting 100% fT > 4xMIC or using higher-dose CKRT, CI would allow for higher PTA than intermittent dosing.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":"12 1","pages":"38"},"PeriodicalIF":3.8,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11459894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142391081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of normal saline versus lactated Ringer's solution on organ function and inflammatory responses to heatstroke in rats. 生理盐水和乳酸林格氏液对大鼠器官功能和中暑炎症反应的影响
IF 3.8 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-10-08 DOI: 10.1186/s40560-024-00746-y
Lan Chen, Chang Liu, Zhaocai Zhang, Yuping Zhang, Xiuqin Feng

Background: Heatstroke is a life-threatening condition characterized by severe hyperthermia and multiple organ dysfunction. Both normal saline (NS) and lactated Ringer's solution (LR) are commonly used for cooling and volume resuscitation in heatstroke patients; however, their specific impacts on patient outcomes during heatstroke management are poorly understood. Given that the systemic inflammatory response and multiple-organ damage caused by heat toxicity are the main pathophysiological features of heatstroke, the aim of this study was to evaluate the effects of NS and LR on the production of inflammatory cytokines and the functional and structural integrity of renal and cardiac tissues in a rat model of heatstroke.

Methods: Fifty-five male Sprague‒Dawley rats were randomly divided into four groups: cold NS or LR infusion postheatstroke (4 ℃, 4 ml/100 g, over 10 min) and NS or LR infusion without heatstroke induction (control groups). Vital signs, arterial blood gases, inflammatory cytokines, and renal and cardiac function indicators, such as serum creatinine and cTnI, were monitored after treatment. Tissue samples were analysed via HE staining, electron microscopy, and fluorescence staining for apoptosis markers, and protein lysates were used for Western blotting of pyroptosis-related proteins.

Results: Compared with LR-treated heatstroke rats, NS-treated heatstroke rats presented lower mean arterial pressures, worsened metabolic acidosis, and higher levels of IL-6 and TNF-α in both the serum and tissue. These rats also presented increased serum creatinine, troponin, catecholamines, and NGAL and reduced renal clearance. Histological and ultrastructural analyses revealed more severe tissue damage in NS-treated rats, with increased apoptosis and increased expression of NLRP3/caspase-1/GSDMD signalling molecules. Similar differences were not observed between the control groups receiving either NS or LR infusion. One NS-treated heatstroke rat died within 24 h, whereas all the LR-treated and control rats survived.

Conclusions: NS resuscitation in heat-exposed rats significantly promotes metabolic acidosis and the inflammatory response, leading to greater functional and structural organ damage than does LR. These findings underscore the necessity of selecting appropriate resuscitation fluids for heatstroke management to minimize organ damage and improve outcomes.

背景:中暑是一种以严重高热和多器官功能障碍为特征的危及生命的疾病。正常生理盐水(NS)和乳酸林格氏液(LR)通常用于中暑患者的降温和容量复苏;然而,人们对它们在中暑处理过程中对患者预后的具体影响知之甚少。鉴于热毒性引起的全身炎症反应和多器官损伤是中暑的主要病理生理特征,本研究旨在评估 NS 和 LR 对中暑大鼠模型中炎症细胞因子的产生以及肾脏和心脏组织的功能和结构完整性的影响:方法:将 55 只雄性 Sprague-Dawley 大鼠随机分为四组:中暑后冷输注 NS 或 LR(4 ℃,4 毫升/100 克,10 分钟)组和未诱导中暑的输注 NS 或 LR 组(对照组)。治疗后监测生命体征、动脉血气、炎症细胞因子、肾功能和心功能指标(如血清肌酐和 cTnI)。组织样本通过 HE 染色、电子显微镜和荧光染色分析细胞凋亡标记物,蛋白裂解液用于 Western 印迹检测热凋亡相关蛋白:结果:与LR处理的中暑大鼠相比,NS处理的中暑大鼠平均动脉压更低,代谢性酸中毒更严重,血清和组织中的IL-6和TNF-α水平更高。这些大鼠的血清肌酐、肌钙蛋白、儿茶酚胺和 NGAL 水平也有所升高,肾脏清除率降低。组织学和超微结构分析表明,NS 处理的大鼠组织损伤更严重,细胞凋亡增加,NLRP3/caspase-1/GSDMD 信号分子表达增加。接受 NS 或 LR 输注的对照组之间没有观察到类似的差异。一只经 NS 处理的中暑大鼠在 24 小时内死亡,而所有经 LR 处理的大鼠和对照组大鼠均存活:结论:与 LR 相比,对热暴露大鼠进行 NS 复苏会显著促进代谢性酸中毒和炎症反应,导致器官功能和结构的更大损伤。这些发现强调了在中暑处理中选择适当复苏液体的必要性,以最大限度地减少器官损伤并改善预后。
{"title":"Effects of normal saline versus lactated Ringer's solution on organ function and inflammatory responses to heatstroke in rats.","authors":"Lan Chen, Chang Liu, Zhaocai Zhang, Yuping Zhang, Xiuqin Feng","doi":"10.1186/s40560-024-00746-y","DOIUrl":"10.1186/s40560-024-00746-y","url":null,"abstract":"<p><strong>Background: </strong>Heatstroke is a life-threatening condition characterized by severe hyperthermia and multiple organ dysfunction. Both normal saline (NS) and lactated Ringer's solution (LR) are commonly used for cooling and volume resuscitation in heatstroke patients; however, their specific impacts on patient outcomes during heatstroke management are poorly understood. Given that the systemic inflammatory response and multiple-organ damage caused by heat toxicity are the main pathophysiological features of heatstroke, the aim of this study was to evaluate the effects of NS and LR on the production of inflammatory cytokines and the functional and structural integrity of renal and cardiac tissues in a rat model of heatstroke.</p><p><strong>Methods: </strong>Fifty-five male Sprague‒Dawley rats were randomly divided into four groups: cold NS or LR infusion postheatstroke (4 ℃, 4 ml/100 g, over 10 min) and NS or LR infusion without heatstroke induction (control groups). Vital signs, arterial blood gases, inflammatory cytokines, and renal and cardiac function indicators, such as serum creatinine and cTnI, were monitored after treatment. Tissue samples were analysed via HE staining, electron microscopy, and fluorescence staining for apoptosis markers, and protein lysates were used for Western blotting of pyroptosis-related proteins.</p><p><strong>Results: </strong>Compared with LR-treated heatstroke rats, NS-treated heatstroke rats presented lower mean arterial pressures, worsened metabolic acidosis, and higher levels of IL-6 and TNF-α in both the serum and tissue. These rats also presented increased serum creatinine, troponin, catecholamines, and NGAL and reduced renal clearance. Histological and ultrastructural analyses revealed more severe tissue damage in NS-treated rats, with increased apoptosis and increased expression of NLRP3/caspase-1/GSDMD signalling molecules. Similar differences were not observed between the control groups receiving either NS or LR infusion. One NS-treated heatstroke rat died within 24 h, whereas all the LR-treated and control rats survived.</p><p><strong>Conclusions: </strong>NS resuscitation in heat-exposed rats significantly promotes metabolic acidosis and the inflammatory response, leading to greater functional and structural organ damage than does LR. These findings underscore the necessity of selecting appropriate resuscitation fluids for heatstroke management to minimize organ damage and improve outcomes.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":"12 1","pages":"39"},"PeriodicalIF":3.8,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11462651/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142391080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recovery of consciousness after acute brain injury: a narrative review. 急性脑损伤后的意识恢复:叙述性综述。
IF 3.8 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-09-26 DOI: 10.1186/s40560-024-00749-9
Satoshi Egawa, Jeremy Ader, Jan Claassen

Background: Disorders of consciousness (DoC) are frequently encountered in both, acute and chronic brain injuries. In many countries, early withdrawal of life-sustaining treatments is common practice for these patients even though the accuracy of predicting recovery is debated and delayed recovery can be seen. In this review, we will discuss theoretical concepts of consciousness and pathophysiology, explore effective strategies for management, and discuss the accurate prediction of long-term clinical outcomes. We will also address research challenges.

Main text: DoC are characterized by alterations in arousal and/or content, being classified as coma, unresponsive wakefulness syndrome/vegetative state, minimally conscious state, and confusional state. Patients with willful modulation of brain activity detectable by functional MRI or EEG but not by behavioral examination is a state also known as covert consciousness or cognitive motor dissociation. This state may be as common as every 4th or 5th patient without behavioral evidence of verbal command following and has been identified as an independent predictor of long-term functional recovery. Underlying mechanisms are uncertain but intact arousal and thalamocortical projections maybe be essential. Insights into the mechanisms underlying DoC will be of major importance as these will provide a framework to conceptualize treatment approaches, including medical, mechanical, or electoral brain stimulation.

Conclusions: We are beginning to gain insights into the underlying mechanisms of DoC, identifying novel advanced prognostication tools to improve the accuracy of recovery predictions, and are starting to conceptualize targeted treatments to support the recovery of DoC patients. It is essential to determine how these advancements can be implemented and benefit DoC patients across a range of clinical settings and global societal systems. The Curing Coma Campaign has highlighted major gaps knowledge and provides a roadmap to advance the field of coma science with the goal to support the recovery of patients with DoC.

背景:意识障碍(DoC)在急性和慢性脑损伤中都经常出现。在许多国家,尽管预测恢复的准确性还存在争议,而且会出现延迟恢复的情况,但早期撤除维持生命的治疗是这些患者的普遍做法。在这篇综述中,我们将讨论意识和病理生理学的理论概念,探讨有效的管理策略,并讨论长期临床结果的准确预测。我们还将讨论研究方面的挑战:意识障碍以唤醒和/或内容的改变为特征,可分为昏迷、无反应清醒综合征/植物状态、微意识状态和混淆状态。功能性核磁共振成像或脑电图可检测到大脑活动的故意调节,但行为检查却检测不到,这种状态也被称为隐蔽意识或认知运动解离。这种状态可能常见于第 4 或第 5 个没有行为证据表明听从口头命令的患者,并且已被确定为长期功能恢复的独立预测因素。其基本机制尚不确定,但完整的唤醒和丘脑皮层投射可能是至关重要的。洞察DoC的内在机制将具有重要意义,因为这将为治疗方法的概念化提供一个框架,包括医疗、机械或选举脑刺激:我们正开始深入了解DoC的内在机制,确定新的先进预后工具以提高康复预测的准确性,并开始构思支持DoC患者康复的针对性治疗方法。确定如何在各种临床环境和全球社会系统中实施这些进展并使昏迷患者受益至关重要。治疗昏迷运动 "强调了知识方面的主要差距,并为推进昏迷科学领域的发展提供了路线图,其目标是为昏迷患者的康复提供支持。
{"title":"Recovery of consciousness after acute brain injury: a narrative review.","authors":"Satoshi Egawa, Jeremy Ader, Jan Claassen","doi":"10.1186/s40560-024-00749-9","DOIUrl":"https://doi.org/10.1186/s40560-024-00749-9","url":null,"abstract":"<p><strong>Background: </strong>Disorders of consciousness (DoC) are frequently encountered in both, acute and chronic brain injuries. In many countries, early withdrawal of life-sustaining treatments is common practice for these patients even though the accuracy of predicting recovery is debated and delayed recovery can be seen. In this review, we will discuss theoretical concepts of consciousness and pathophysiology, explore effective strategies for management, and discuss the accurate prediction of long-term clinical outcomes. We will also address research challenges.</p><p><strong>Main text: </strong>DoC are characterized by alterations in arousal and/or content, being classified as coma, unresponsive wakefulness syndrome/vegetative state, minimally conscious state, and confusional state. Patients with willful modulation of brain activity detectable by functional MRI or EEG but not by behavioral examination is a state also known as covert consciousness or cognitive motor dissociation. This state may be as common as every 4th or 5th patient without behavioral evidence of verbal command following and has been identified as an independent predictor of long-term functional recovery. Underlying mechanisms are uncertain but intact arousal and thalamocortical projections maybe be essential. Insights into the mechanisms underlying DoC will be of major importance as these will provide a framework to conceptualize treatment approaches, including medical, mechanical, or electoral brain stimulation.</p><p><strong>Conclusions: </strong>We are beginning to gain insights into the underlying mechanisms of DoC, identifying novel advanced prognostication tools to improve the accuracy of recovery predictions, and are starting to conceptualize targeted treatments to support the recovery of DoC patients. It is essential to determine how these advancements can be implemented and benefit DoC patients across a range of clinical settings and global societal systems. The Curing Coma Campaign has highlighted major gaps knowledge and provides a roadmap to advance the field of coma science with the goal to support the recovery of patients with DoC.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":"12 1","pages":"37"},"PeriodicalIF":3.8,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11425956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142348260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author's response to the letter "Japanese clinical practice guidelines for rehabilitation in critically ill patients 2023 (J-ReCIP 2023)". 作者对 "日本重症患者康复临床实践指南 2023(J-ReCIP 2023)"信函的回复。
IF 3.8 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-09-26 DOI: 10.1186/s40560-024-00751-1
Fumihito Kasai, Yuki Iida, Takeshi Unoki

Recently, a Letter to the Editor critiquing the recommendations of the Japanese Clinical Practice Guidelines for Rehabilitation in Critically Ill Patients, 2023, was published. The comment centered on the recommendation, "Weak recommendation against the use of endoscopy-based management (GRADE 2D: certainty of evidence = 'very low')" for the clinical question, "Should critically ill patients be managed based on video endoscopic assessment of swallowing?" In response, we outline the rationale behind our recommendations and their clinical implications.

最近,有一封致编辑的信对《日本重症患者康复临床实践指南(2023 年)》的建议进行了批评。评论主要针对临床问题 "是否应根据视频内镜评估吞咽情况对重症患者进行管理?"提出的建议,即 "反对使用基于内镜的管理(GRADE 2D:证据确定性='非常低')"。对此,我们概述了我们提出建议的理由及其临床意义。
{"title":"Author's response to the letter \"Japanese clinical practice guidelines for rehabilitation in critically ill patients 2023 (J-ReCIP 2023)\".","authors":"Fumihito Kasai, Yuki Iida, Takeshi Unoki","doi":"10.1186/s40560-024-00751-1","DOIUrl":"https://doi.org/10.1186/s40560-024-00751-1","url":null,"abstract":"<p><p>Recently, a Letter to the Editor critiquing the recommendations of the Japanese Clinical Practice Guidelines for Rehabilitation in Critically Ill Patients, 2023, was published. The comment centered on the recommendation, \"Weak recommendation against the use of endoscopy-based management (GRADE 2D: certainty of evidence = 'very low')\" for the clinical question, \"Should critically ill patients be managed based on video endoscopic assessment of swallowing?\" In response, we outline the rationale behind our recommendations and their clinical implications.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":"12 1","pages":"36"},"PeriodicalIF":3.8,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11426105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142348259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Remifentanil vs. dexmedetomidine for cardiac surgery patients with noninvasive ventilation intolerance: a multicenter randomized controlled trial 雷米芬太尼与右美托咪定治疗无创通气不耐受的心脏手术患者:多中心随机对照试验
IF 7.1 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-09-18 DOI: 10.1186/s40560-024-00750-2
Guang-wei Hao, Jia-qing Wu, Shen-ji Yu, Kai Liu, Yan Xue, Qian Gong, Rong-cheng Xie, Guo-guang Ma, Ying Su, Jun-yi Hou, Yi-jie zhang, Wen-jun Liu, Wei Li, Guo-wei Tu, Zhe Luo
The optimal sedative regime for noninvasive ventilation (NIV) intolerance remains uncertain. The present study aimed to assess the efficacy and safety of remifentanil (REM) compared to dexmedetomidine (DEX) in cardiac surgery patients with moderate-to-severe intolerance to NIV. In this multicenter, prospective, single-blind, randomized controlled study, adult cardiac surgery patients with moderate-to-severe intolerance to NIV were enrolled and randomly assigned to be treated with either REM or DEX for sedation. The status of NIV intolerance was evaluated using a four-point NIV intolerance score at different timepoints within a 72-h period. The primary outcome was the mitigation rate of NIV intolerance following sedation. A total of 179 patients were enrolled, with 89 assigned to the REM group and 90 to the DEX group. Baseline characteristics were comparable between the two groups, including NIV intolerance score [3, interquartile range (IQR) 3–3 vs. 3, IQR 3–4, p = 0.180]. The chi-squared test showed that mitigation rate, defined as the proportion of patients who were relieved from their initial intolerance status, was not significant at most timepoints, except for the 15-min timepoint (42% vs. 20%, p = 0.002). However, after considering the time factor, generalized estimating equations showed that the difference was statistically significant, and REM outperformed DEX (odds ratio = 3.31, 95% confidence interval: 1.35–8.12, p = 0.009). Adverse effects, which were not reported in the REM group, were encountered by nine patients in the DEX group, with three instances of bradycardia and six cases of severe hypotension. Secondary outcomes, including NIV failure (5.6% vs. 7.8%, p = 0.564), tracheostomy (1.12% vs. 0%, p = 0.313), ICU LOS (7.7 days, IQR 5.8–12 days vs. 7.0 days, IQR 5–10.6 days, p = 0.219), and in-hospital mortality (1.12% vs. 2.22%, p = 0.567), demonstrated comparability between the two groups. In summary, our study demonstrated no significant difference between REM and DEX in the percentage of patients who achieved mitigation among cardiac surgery patients with moderate-to-severe NIV intolerance. However, after considering the time factor, REM was significantly superior to DEX. Trial registration ClinicalTrials.gov (NCT04734418), registered on January 22, 2021. URL of the trial registry record: https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S000AM4S&selectaction=Edit&uid=U00038YX&ts=3&cx=eqn1z0 .
无创通气(NIV)不耐受的最佳镇静方案仍不确定。本研究旨在评估瑞芬太尼(REM)与右美托咪定(DEX)相比,对无创通气中重度不耐受的心脏手术患者的疗效和安全性。在这项多中心、前瞻性、单盲、随机对照研究中,对 NIV 中度至重度不耐受的成人心脏手术患者被纳入研究,并随机分配接受 REM 或 DEX 镇静治疗。在 72 小时内的不同时间点,使用四点 NIV 不耐受评分来评估 NIV 不耐受状况。主要结果是镇静后呼吸机不耐受的缓解率。共有 179 名患者入选,其中 89 人被分配到 REM 组,90 人被分配到 DEX 组。两组患者的基线特征相当,包括NIV不耐受评分[3,四分位数间距(IQR)3-3 vs. 3,IQR 3-4,p = 0.180]。卡方检验显示,缓解率(定义为从最初的不耐受状态中缓解的患者比例)在大多数时间点均无显著性差异,但 15 分钟时间点除外(42% 对 20%,P = 0.002)。然而,在考虑了时间因素后,广义估计方程显示差异具有统计学意义,且 REM 的效果优于 DEX(几率比 = 3.31,95% 置信区间:1.35-8.12,p = 0.009)。REM组未出现不良反应,而DEX组有9名患者出现了不良反应,其中3例为心动过缓,6例为严重低血压。次要结果包括 NIV 失败(5.6% vs. 7.8%,p = 0.564)、气管切开(1.12% vs. 0%,p = 0.313)、ICU LOS(7.7 天,IQR 5.8-12 天 vs. 7.0 天,IQR 5-10.6 天,p = 0.219)和院内死亡率(1.12% vs. 2.22%,p = 0.567),两组结果具有可比性。总之,我们的研究表明,在中重度 NIV 不耐受的心脏手术患者中,REM 和 DEX 在实现缓解的患者比例上没有显著差异。但是,考虑到时间因素,REM明显优于DEX。试验注册 ClinicalTrials.gov(NCT04734418),注册日期为 2021 年 1 月 22 日。试验登记记录网址:https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S000AM4S&selectaction=Edit&uid=U00038YX&ts=3&cx=eqn1z0 。
{"title":"Remifentanil vs. dexmedetomidine for cardiac surgery patients with noninvasive ventilation intolerance: a multicenter randomized controlled trial","authors":"Guang-wei Hao, Jia-qing Wu, Shen-ji Yu, Kai Liu, Yan Xue, Qian Gong, Rong-cheng Xie, Guo-guang Ma, Ying Su, Jun-yi Hou, Yi-jie zhang, Wen-jun Liu, Wei Li, Guo-wei Tu, Zhe Luo","doi":"10.1186/s40560-024-00750-2","DOIUrl":"https://doi.org/10.1186/s40560-024-00750-2","url":null,"abstract":"The optimal sedative regime for noninvasive ventilation (NIV) intolerance remains uncertain. The present study aimed to assess the efficacy and safety of remifentanil (REM) compared to dexmedetomidine (DEX) in cardiac surgery patients with moderate-to-severe intolerance to NIV. In this multicenter, prospective, single-blind, randomized controlled study, adult cardiac surgery patients with moderate-to-severe intolerance to NIV were enrolled and randomly assigned to be treated with either REM or DEX for sedation. The status of NIV intolerance was evaluated using a four-point NIV intolerance score at different timepoints within a 72-h period. The primary outcome was the mitigation rate of NIV intolerance following sedation. A total of 179 patients were enrolled, with 89 assigned to the REM group and 90 to the DEX group. Baseline characteristics were comparable between the two groups, including NIV intolerance score [3, interquartile range (IQR) 3–3 vs. 3, IQR 3–4, p = 0.180]. The chi-squared test showed that mitigation rate, defined as the proportion of patients who were relieved from their initial intolerance status, was not significant at most timepoints, except for the 15-min timepoint (42% vs. 20%, p = 0.002). However, after considering the time factor, generalized estimating equations showed that the difference was statistically significant, and REM outperformed DEX (odds ratio = 3.31, 95% confidence interval: 1.35–8.12, p = 0.009). Adverse effects, which were not reported in the REM group, were encountered by nine patients in the DEX group, with three instances of bradycardia and six cases of severe hypotension. Secondary outcomes, including NIV failure (5.6% vs. 7.8%, p = 0.564), tracheostomy (1.12% vs. 0%, p = 0.313), ICU LOS (7.7 days, IQR 5.8–12 days vs. 7.0 days, IQR 5–10.6 days, p = 0.219), and in-hospital mortality (1.12% vs. 2.22%, p = 0.567), demonstrated comparability between the two groups. In summary, our study demonstrated no significant difference between REM and DEX in the percentage of patients who achieved mitigation among cardiac surgery patients with moderate-to-severe NIV intolerance. However, after considering the time factor, REM was significantly superior to DEX. Trial registration ClinicalTrials.gov (NCT04734418), registered on January 22, 2021. URL of the trial registry record: https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S000AM4S&selectaction=Edit&uid=U00038YX&ts=3&cx=eqn1z0 .","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":"7 1","pages":""},"PeriodicalIF":7.1,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142250907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between red blood cell distribution width and 30-day mortality in critically ill septic patients: a propensity score-matched study 脓毒症重症患者红细胞分布宽度与 30 天死亡率之间的关系:倾向得分匹配研究
IF 7.1 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-09-18 DOI: 10.1186/s40560-024-00747-x
Yu-Cheng Wu, Hsin-Hua Chen, Wen-Cheng Chao
Sepsis is the leading cause of death worldwide, and a number of biomarkers have been developed for early mortality risk stratification. Red blood cell distribution width (RDW) is a routinely available hematological data and has been found to be associated with mortality in a number of diseases; therefore, we aim to address the association between RDW and mortality in critically ill patients with sepsis. We analyzed data of critically ill adult patients with sepsis on the TriNetX platform, excluding those with hematologic malignancies, thalassemia, and iron deficiency anemia. Propensity score-matching (PSM) (1:1) was used to mitigate confounding effects, and hazard ratio (HR) with 95% confidence (CI) was calculated to determine the association between RDW and 30-day mortality. We further conducted sensitivity analyses through using distinct cut-points of RDW and severities of sepsis. A total of 256,387 critically ill septic patients were included in the analysis, and 40.0% of them had RDW equal to or higher than 16%. After PSM, we found that high RDW was associated with an increased 30-day mortality rate (HR: 1.887, 95% CI 1.847–1.928). The associations were consistent using distinct cut-points of RDW, with the strength of association using cut-points of 12%, 14%, 16%, 18% and 20% were 2.098, 2.204, 1.887, 1.809 and 1.932, respectively. Furthermore, we found consistent associations among critically ill septic patients with distinct severities, with the association among those with shock, receiving mechanical ventilation, bacteremia and requirement of hemodialysis being 1.731, 1.735, 2.380 and 1.979, respectively. We found that RDW was associated with 30-day mortality in critically ill septic patients, underscoring the potential as a prognostic marker in sepsis. More studies are needed to explore the underlying mechanisms.
脓毒症是全球死亡的主要原因,目前已开发出许多生物标志物用于早期死亡风险分层。红细胞分布宽度(RDW)是一种常规的血液学数据,已被发现与多种疾病的死亡率有关;因此,我们旨在研究红细胞分布宽度与脓毒症重症患者死亡率之间的关系。我们分析了 TriNetX 平台上脓毒症成人重症患者的数据,排除了血液恶性肿瘤、地中海贫血和缺铁性贫血患者。我们采用倾向评分匹配(PSM)(1:1)来减轻混杂效应,并计算了危险比(HR)和 95% 置信度(CI),以确定 RDW 与 30 天死亡率之间的关系。我们还通过使用不同的 RDW 切点和败血症严重程度进行了敏感性分析。共有 256387 名重症脓毒症患者被纳入分析,其中 40.0% 的患者的 RDW 等于或高于 16%。经过 PSM 分析,我们发现高 RDW 与 30 天死亡率的增加有关(HR:1.887,95% CI 1.847-1.928)。使用不同的 RDW 切点可以得出一致的关联,使用 12%、14%、16%、18% 和 20% 的切点得出的关联强度分别为 2.098、2.204、1.887、1.809 和 1.932。此外,我们还发现不同严重程度的重症脓毒症患者之间存在一致的相关性,休克、接受机械通气、菌血症和需要血液透析的患者之间的相关性分别为 1.731、1.735、2.380 和 1.979。我们发现,RDW 与重症脓毒症患者的 30 天死亡率相关,这表明它有可能成为脓毒症的预后标志物。还需要更多的研究来探索其潜在机制。
{"title":"Association between red blood cell distribution width and 30-day mortality in critically ill septic patients: a propensity score-matched study","authors":"Yu-Cheng Wu, Hsin-Hua Chen, Wen-Cheng Chao","doi":"10.1186/s40560-024-00747-x","DOIUrl":"https://doi.org/10.1186/s40560-024-00747-x","url":null,"abstract":"Sepsis is the leading cause of death worldwide, and a number of biomarkers have been developed for early mortality risk stratification. Red blood cell distribution width (RDW) is a routinely available hematological data and has been found to be associated with mortality in a number of diseases; therefore, we aim to address the association between RDW and mortality in critically ill patients with sepsis. We analyzed data of critically ill adult patients with sepsis on the TriNetX platform, excluding those with hematologic malignancies, thalassemia, and iron deficiency anemia. Propensity score-matching (PSM) (1:1) was used to mitigate confounding effects, and hazard ratio (HR) with 95% confidence (CI) was calculated to determine the association between RDW and 30-day mortality. We further conducted sensitivity analyses through using distinct cut-points of RDW and severities of sepsis. A total of 256,387 critically ill septic patients were included in the analysis, and 40.0% of them had RDW equal to or higher than 16%. After PSM, we found that high RDW was associated with an increased 30-day mortality rate (HR: 1.887, 95% CI 1.847–1.928). The associations were consistent using distinct cut-points of RDW, with the strength of association using cut-points of 12%, 14%, 16%, 18% and 20% were 2.098, 2.204, 1.887, 1.809 and 1.932, respectively. Furthermore, we found consistent associations among critically ill septic patients with distinct severities, with the association among those with shock, receiving mechanical ventilation, bacteremia and requirement of hemodialysis being 1.731, 1.735, 2.380 and 1.979, respectively. We found that RDW was associated with 30-day mortality in critically ill septic patients, underscoring the potential as a prognostic marker in sepsis. More studies are needed to explore the underlying mechanisms.","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":"165 1","pages":""},"PeriodicalIF":7.1,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142250908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Which factors are associated with acquired weakness in the ICU? An overview of systematic reviews and meta-analyses. 哪些因素与重症监护室中的后天虚弱有关?系统回顾和荟萃分析综述。
IF 3.8 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-09-05 DOI: 10.1186/s40560-024-00744-0
Rocío Fuentes-Aspe, Ruvistay Gutierrez-Arias, Felipe González-Seguel, Gabriel Nasri Marzuca-Nassr, Rodrigo Torres-Castro, Jasim Najum-Flores, Pamela Seron

Rationale: Intensive care unit-acquired weakness (ICUAW) is common in critically ill patients, characterized by muscle weakness and physical function loss. Determining risk factors for ICUAW poses challenges due to variations in assessment methods and limited generalizability of results from specific populations, the existing literature on these risk factors lacks a clear and comprehensive synthesis.

Objective: This overview aimed to synthesize risk factors for ICUAW, categorizing its modifiable and nonmodifiable factors.

Methods: An overview of systematic reviews was conducted. Six relevant databases were searched for systematic reviews. Two pairs of reviewers selected reviews following predefined criteria, where bias was evaluated. Results were qualitatively summarized and an overlap analysis was performed for meta-analyses.

Results: Eighteen systematic reviews were included, comprising 24 risk factors for ICUAW. Meta-analyses were performed for 15 factors, while remaining reviews provided qualitative syntheses. Twelve reviews had low risk of bias, 4 reviews were unclear, and 2 reviews exhibited high risk of bias. The extent of overlap ranged from 0 to 23% for the corrected covered area index. Nonmodifiable factors, including advanced age, female gender, and multiple organ failure, were consistently associated with ICUAW. Modifiable factors, including neuromuscular blocking agents, hyperglycemia, and corticosteroids, yielded conflicting results. Aminoglycosides, renal replacement therapy, and norepinephrine were associated with ICUAW but with high heterogeneity.

Conclusions: Multiple risk factors associated with ICUAW were identified, warranting consideration in prevention and treatment strategies. Some risk factors have produced conflicting results, and several remain underexplored, emphasizing the ongoing need for personalized studies encompassing all potential contributors to ICUAW development.

理由:重症监护病房获得性乏力(ICUAW)在重症患者中很常见,其特点是肌肉无力和身体功能丧失。由于评估方法的不同以及特定人群评估结果的可推广性有限,确定重症监护病房获得性肌无力的风险因素是一项挑战,现有文献对这些风险因素缺乏明确而全面的综述:本综述旨在综合 ICUAW 的风险因素,对其可改变和不可改变的因素进行分类:方法:对系统综述进行了概述。对六个相关数据库进行了系统综述检索。两对审稿人按照预先确定的标准选择综述,并对偏倚进行评估。对结果进行了定性总结,并对荟萃分析进行了重叠分析:结果:共纳入了 18 篇系统综述,其中包括 24 个导致 ICUAW 的风险因素。对 15 个因素进行了元分析,其余综述进行了定性总结。12篇综述存在低偏倚风险,4篇综述不明确,2篇综述存在高偏倚风险。校正覆盖面积指数的重叠程度从 0% 到 23% 不等。包括高龄、女性和多器官功能衰竭在内的不可改变因素始终与ICUAW相关。包括神经肌肉阻滞剂、高血糖和皮质类固醇在内的可改变因素产生了相互矛盾的结果。氨基糖苷类药物、肾脏替代治疗和去甲肾上腺素与ICUAW相关,但异质性很高:结论:发现了与 ICUAW 相关的多种风险因素,值得在预防和治疗策略中加以考虑。一些风险因素产生了相互矛盾的结果,还有一些因素仍未得到充分探讨,这就强调了目前需要进行个性化研究,以涵盖 ICUAW 发生的所有潜在因素。
{"title":"Which factors are associated with acquired weakness in the ICU? An overview of systematic reviews and meta-analyses.","authors":"Rocío Fuentes-Aspe, Ruvistay Gutierrez-Arias, Felipe González-Seguel, Gabriel Nasri Marzuca-Nassr, Rodrigo Torres-Castro, Jasim Najum-Flores, Pamela Seron","doi":"10.1186/s40560-024-00744-0","DOIUrl":"10.1186/s40560-024-00744-0","url":null,"abstract":"<p><strong>Rationale: </strong>Intensive care unit-acquired weakness (ICUAW) is common in critically ill patients, characterized by muscle weakness and physical function loss. Determining risk factors for ICUAW poses challenges due to variations in assessment methods and limited generalizability of results from specific populations, the existing literature on these risk factors lacks a clear and comprehensive synthesis.</p><p><strong>Objective: </strong>This overview aimed to synthesize risk factors for ICUAW, categorizing its modifiable and nonmodifiable factors.</p><p><strong>Methods: </strong>An overview of systematic reviews was conducted. Six relevant databases were searched for systematic reviews. Two pairs of reviewers selected reviews following predefined criteria, where bias was evaluated. Results were qualitatively summarized and an overlap analysis was performed for meta-analyses.</p><p><strong>Results: </strong>Eighteen systematic reviews were included, comprising 24 risk factors for ICUAW. Meta-analyses were performed for 15 factors, while remaining reviews provided qualitative syntheses. Twelve reviews had low risk of bias, 4 reviews were unclear, and 2 reviews exhibited high risk of bias. The extent of overlap ranged from 0 to 23% for the corrected covered area index. Nonmodifiable factors, including advanced age, female gender, and multiple organ failure, were consistently associated with ICUAW. Modifiable factors, including neuromuscular blocking agents, hyperglycemia, and corticosteroids, yielded conflicting results. Aminoglycosides, renal replacement therapy, and norepinephrine were associated with ICUAW but with high heterogeneity.</p><p><strong>Conclusions: </strong>Multiple risk factors associated with ICUAW were identified, warranting consideration in prevention and treatment strategies. Some risk factors have produced conflicting results, and several remain underexplored, emphasizing the ongoing need for personalized studies encompassing all potential contributors to ICUAW development.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":"12 1","pages":"33"},"PeriodicalIF":3.8,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11375885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Intensive Care
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1